Results 131 to 140 of about 20,100 (304)
Haematologica, 2007 Paroxysmal nocturnal hemoglobinuria (PNH) is characterized by intravascular hemolysis leading to anemia and other clinical manifestations. Transfusions are often required to support hemoglobin at tolerable levels.
A. Hill +3 more
doaj +1 more source
The Complement Inhibitor Eculizumab in Paroxysmal Nocturnal Hemoglobinuria [PDF]
, 2006 Peter Hillmen +19 more
openalex +1 more source
Advances in Hematology, 2014 Eculizumab is highly effective in controlling complement activation in patients with the atypical hemolytic uremic syndrome (aHUS). However, the course of responses to the treatment is not well understood. We reviewed the responses to eculizumab therapy
Han-Mou Tsai, Elizabeth Kuo
doaj +1 more source
Frontiers in Immunology, 2019 The treatment of paroxysmal nocturnal hemoglobinuria has been revolutionized by the introduction of the anti-C5 agent eculizumab; however, eculizumab is not the cure for Paroxysmal nocturnal hemoglobinuria (PNH), and room for improvement remains. Indeed,
Antonio M. Risitano +15 more
doaj +1 more source
Atypical haemolytic-uraemic syndrome caused by factor H mutation: case report and new management strategies in children [PDF]
, 2012 Atypical haemolytic uraemic syndrome is causedby alternative complement pathway dysregulation. It has recently been recognised that most cases are due to genetic factors and a growing list of mutations has been described.
Araújo, L. +5 more
core
Eculizumab prevents anti-ganglioside antibody-mediated neuropathy in a murine model [PDF]
, 2008 Susan K. Halstead +8 more
openalex +1 more source
Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome.
New England Journal of Medicine, 2013 BACKGROUND Atypical hemolytic-uremic syndrome is a genetic, life-threatening, chronic disease of complement-mediated thrombotic microangiopathy. Plasma exchange or infusion may transiently maintain normal levels of hematologic measures but does not treat
C. Legendre +32 more
semanticscholar +1 more source
Case Reports in Transplantation, 2017 Thrombotic microangiopathy is a form of antibody-mediated rejection (ABMR): it is the main complication of ABO-incompatible (ABOi) kidney transplantation (KT). Herein, we report on two cases of ABMR with biological and histological features of thrombotic
Luca Lanfranco +8 more
doaj +1 more source
Which Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Should Be Treated with Eculizumab? [PDF]
, 2008 Richard L. Haspel, Peter Hillmen
openalex +1 more source